BACKGROUND: The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. METHODS: We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. RESULTS: At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non-community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001). CONCLUSIONS: Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients / M.F. Di Pasquale, G. Sotgiu, A. Gramegna, D. Radovanovic, S. Terraneo, L.F. Reyes, J. Rupp, J. González del Castillo, F. Blasi, S. Aliberti, M.I. Restrepo, P.K. Aruj, S. Attorri, E. Barimboim, J.P. Caeiro, M.I. Garzón, V.H. Cambursano, A. Cazaux, A. Ceccato, J. Chertcoff, F. Lascar, F.D. Tulio, A.C. Díaz, L. de Vedia, M.C. Ganaha, S. Lambert, G. Lopardo, C.M. Luna, A.G. Malberti, N. Morcillo, S. Tartara, A.A. Cetrangolo, C. Pensotti, B. Pereyra, P.G. Scapellato, J.P. Stagnaro, S. Shah, F. Lötsch, F. Thalhammer, K. Anseeuw, C.A. Francois, E. Van Braeckel, J.L. Vincent, M.Z. Djimon, J. Bashi, R. Dodo, S.A. Nouér, P. Chipev, M. Encheva, D. Miteva, D. Petkova, A.D. Balkissou, E.W.P. Yone, B.H.M. Ngahane, N. Shen, J. Xu, C.A.B. Rico, R. Buitrago, F.J.P. Paternina, J.K. Ntumba, V.V. Carevic, M. Jakopovic, M. Jankovic, Z. Matkovic, I. Mitrecic, M.B. Jacobsson, A.B. Christensen, U.C.H. Bødtger, C.N. Meyer, A.V. Jensen, G. Baunbæk-Knudsen, P.T. Petersen, S. Andersen, I.E.A. El-Wahhab, N.E. Morsy, H. Shafiek, E. Sobh, K.A. Abdulsemed, F. Bertrand, C. Brun-Buisson, E. de Montmollin, M. Fartoukh, J. Messika, P. Tattevin, A. Khoury, B. Ebruke, M. Dreher, M. Kolditz, M. Meisinger, K. Niederlausitz, M.W. Pletz, S. Hagel, J. Rupp, T. Schaberg, M. Spielmanns, P. Creutz, N. Suttorp, B. Siaw-Lartey, K. Dimakou, D. Papapetrou, E. Tsigou, D. Ampazis, E. Kaimakamis, M. Bhatia, R. Dhar, G. D’Souza, R. Garg, P.A. Koul, P.A. Mahesh, B.S. Jayaraj, K.V. Narayan, H.B. Udnur, S.B. Krishnamurthy, S. Kant, R. Swarnakar, S. Limaye, S. Salvi, K. Golshani, V.M. Keatings, I. Martin-Loeches, Y. Maor, J. Strahilevitz, S. Battaglia, M. Carrabba, P. Ceriana, M. Confalonieri, A.d. Monforte, B.D. Prato, M.D. Rosa, R. Fantini, G. Fiorentino, M.A. Gammino, F. Menzella, G. Milani, S. Nava, G. Palmiero, R. Petrino, B. Gabrielli, P. Rossi, C. Sorino, G. Steinhilber, A. Zanforlin, F. Franzetti, M. Carugati, M. Morosi, E. Monge, M. Carone, V. Patella, S. Scarlata, A. Comel, K. Kurahashi, Z.A. Bacha, D.B. Ugalde, O.C. Zuñiga, J.F. Villegas, M. Medenica, E.M.W. van de Garde, D.R. Mihsra, P. Shrestha, E. Ridgeon, B.I. Awokola, O.N.O. Nwankwo, A.B. Olufunlola, S. Olumide, K.N. Ukwaja, M. Irfan, L. Minarowski, S. Szymon, F. Froes, P. Leuschner, M. Meireles, C. Ferrão, P. Leuschner, J. Neves, S.B. Ravara, V. Brocovschii, C. Ion, D. Rusu, C. Toma, D. Chirita, C.M. Dorobat, A. Birkun, A. Kaluzhenina, A. Almotairi, Z.A.A. Bukhary, J. Edathodu, A. Fathy, A.M.A. Enani, N.E. Mohamed, J.U. Memon, A. Bella, N. Bogdanović, B. Milenkovic, D. Pesut, L. Borderìas, N.M.B. Garcia, H.C. Alarcón, C. Cilloniz, A. Torres, V. Diaz-Brito, X. Casas, A.E. González, M.L. Fernández-Almira, M. Gallego, I. Gaspar-GarcÍa, J.G. del Castillo, P.J. Victoria, E.L. Martínez, R.M. de Molina, P.J. Marcos, R. Menéndez, A. Pando-Sandoval, C.P. Aymerich, A.L. de la Torre, I. García-Olivé, J. Rello, S. Moyano, F. Sanz, O. Sibila, A. Rodrigo-Troyano, J. Solé-Violán, A. Uranga, J.F.M. van Boven, E.V. Torra, J.A. Pujol, C. Feldman, H.K. Yum, A.A. Fiogbe, F. Yangui, S. Bilaceroglu, L. Dalar, U. Yilmaz, A. Bogomolov, N. Elahi, D.J. Dhasmana, A. Feneley, R. Ions, J. Skeemer, G. Woltmann, C. Hancock, A.T. Hill, B. Rudran, S. Ruiz-Buitrago, M. Campbell, P. Whitaker, A. Youzguin, A. Singanayagam, K.S. Allen, V. Brito, J. Dietz, C.E. Dysart, S.M. Kellie, R.A. Franco-Sadud, G. Meier, M. Gaga, T.L. Holland, S.P. Bergin, F. Kheir, M. Landmeier, M. Lois, G.B. Nair, H. Patel, K. Reyes, W. Rodriguez-Cintron, S. Saito, N.J. Soni, J. Noda, C.I. Hinojosa, S.M. Levine, L.F. Angel, A. Anzueto, K.S. Whitlow, J. Hipskind, K. Sukhija, V. Totten, R.G. Wunderink, R.D. Shah, K.J. Mateyo, L. Noriega, E. Alvarado, M. Aman, L. Labra. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 68:9(2019), pp. 1482-1493. [10.1093/cid/ciy723]

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

A. Gramegna;D. Radovanovic;S. Terraneo;F. Blasi;S. Aliberti;M. Carrabba;A.D. Monforte;
2019

Abstract

BACKGROUND: The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. METHODS: We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. RESULTS: At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non-community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001). CONCLUSIONS: Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.
MRSA; immunocompromise; microbiology; multidrug-resistant pathogens; pneumonia
Settore MED/10 - Malattie dell'Apparato Respiratorio
2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
prevalence and etiology of community-acquired pneumonia in immunocompromised patients CID 2019.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 11.46 MB
Formato Adobe PDF
11.46 MB Adobe PDF Visualizza/Apri
prevalence and etiology of community-acquired pneumonia in immunocompromised patients CID 2019-compresso.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 562.62 kB
Formato Adobe PDF
562.62 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/640958
Citazioni
  • ???jsp.display-item.citation.pmc??? 49
  • Scopus 112
  • ???jsp.display-item.citation.isi??? 95
social impact